Instil Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 155.50K shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 129.91K shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-06-30 was 0.00 shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-03-31 was 3.69M shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 70.25K shares, a 219.71% increase from fiscal 2024.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 21.97K shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 52.45K shares, a 98.68% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 70.25K shares 10-K · filed 2026-03-27 | |
| 2024-12-31 | 21.97K shares 10-K · filed 2026-03-27 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-04 | |
| 2022-12-31 | 52.45K shares 10-K · filed 2024-03-21 | |
| 2021-12-31 | 155.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 3.98M shares 10-K · filed 2023-03-31 |
| 2021-09-30 | 129.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 3.69M shares 10-Q · filed 2021-05-13 | |
| 2020-12-31 | 591.82K shares 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |